AXSM Axsome Therapeutics Inc
Company Analysis
Latest News
Axsome Posts 46% Revenue Growth and a New Drug Filing — But Can It Turn Momentum Into Profit Before Cash Runs Thin?
Shares of Axsome Therapeutics surged 6% to $234.24 after the brain-health drugmaker reported Q2 results that showed accelerating demand across its product...
🟢 Axsome Therapeutics is trading 6% up in pre-market after 46% Q2 revenue growth
Axsome Therapeutics is trading 6.04% up at $234.24 after August 10, 2026, Q2 results highlighted 46% revenue growth and accelerating AUVELITY demand. -...
🟢 Axsome Therapeutics is trading 4.35% up today after reporting 46% year-over-year revenue growth
Axsome Therapeutics is trading 4.35% up at $222 after reporting second-quarter revenue of $218.4 million, up 46% year over year, driven by Auvelity sales and...
Axsome Therapeutics' second quarter 2026 revenue grew 46% as Auvelity sales beat estimates
Axsome Therapeutics reported second quarter 2026 total revenue of $218.4 million, a 46% year-over-year increase, primarily driven by the performance of its...
Axsome Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 10, 2026
Axsome Therapeutics is expected to report Q2 2026 revenue of $221.11 million and a consensus loss of $0.99 per share, with the stock currently trading at...
🔴 Axsome Therapeutics is trading 4.1% down today after BlackRock reduces stake by 30%
Axsome Therapeutics is trading 4.1% down today at $208.96 following news that BlackRock significantly reduced its position in the company. • BlackRock...
BlackRock Substantially Reduces Stake in Axsome Therapeutics by 30%
On August 1, 2026, it was reported that BlackRock Inc. had significantly reduced its stake in Axsome Therapeutics, selling 1,176,341 shares on June 30, 2026....
🔴 Axsome Therapeutics is trading 5.2% down today on profit-taking after a multi-week rally
Axsome Therapeutics is trading 5.2% down at $222.35 as investors lock in gains following a strong multi-week rally fueled by enthusiasm for its CNS drug...
🔴 Axsome Therapeutics is trading 5.2% down today on potential profit-taking after last week's gains
Axsome Therapeutics is trading at $225.99 (5.2% down) in pre-market as the stock pulls back from last week's rally in the absence of new catalysts. • No fresh...
🔴 Axsome Therapeutics is trading 4.2% down today with no clear company-specific catalyst found
Axsome Therapeutics is trading at $231.00 (-4.15%) in after-hours trading following a session with no confirmed company-specific news to account for the...
Axsome Therapeutics Eyes $310 Target, Following BMO Capital Outperform Rating
BMO Capital initiated coverage of Axsome Therapeutics Inc. on July 21, 2026. The firm issued an Outperform rating for the stock. Analysts set a price target of...
🟢 Axsome Therapeutics is trading 4.1% up today amid biotech sector gains and CNS pipeline optimism
Axsome Therapeutics is trading 4.1% up now at $230.64, rebounding after recent pullbacks amid strong biotech sector gains and optimism surrounding its CNS...
Axsome Announces FDA Acceptance of New Drug Application for AXS-12 in Narcolepsy
Axsome Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for AXS-12 (reboxetine),...
🔴 Axsome Therapeutics is trading 4.3% down today on profit-taking after recent FDA label expansion rally
Axsome Therapeutics is trading at $238.24 (4.3% down) as investors lock in gains following a significant rally driven by regulatory milestones and strong...
🟢 AXSM surges 4.1% today on Phase 3 trial initiation for ADHD treatment
AXSM is trading 4.1% up now at $252.41 following the initiation of its FOCUS-2 Phase 3 trial for solriamfetol in children with ADHD. • This significant...
🔴 AXSM is trading 4% down today as investors take profits after a post-earnings rally
AXSM is trading at $234.97 (4% down) in pre-market, pulling back from a strong run following its Q1 2026 earnings and Auvelity-related optimism. • The stock...
🟢 AXSM is trading 4.1% up today after TD Cowen raised its price target following Auvelity's FDA approval
AXSM is trading 4.1% up at $247.06 as the stock extends a strong multi-week rally driven by positive regulatory developments and bullish analyst sentiment. •...
🔴 Axsome Therapeutics Inc is trading 35.3% down today with no clear company-specific catalyst
Axsome Therapeutics Inc is trading at $163.19 (-35.28%) in after-hours trading following a sharp drop from the regular-session close, despite no immediate...
🟢 Axsome Therapeutics Inc is trading 8.5% up today after presenting new data at SLEEP 2026 conference
Axsome Therapeutics Inc is trading 8.5% up at $275.00 in pre-market, extending a strong multi-day uptrend. • The company announced new data presentations on...
Axsome Therapeutics Price Target Raised to $380, Forecasting $6B Auvelity Sales
Jefferies raised its price target for Axsome Therapeutics (NASDAQ: AXSM) to $380 from $275. The firm maintained its Buy rating, noting significant upside from...